Pharmaceutical Approach
To Oral Pain Relief
InvisiRelief™ is a medicated chewing gum designed to deliver rapid, localised comfort for oral and orthodontic discomfort. Now advancing into pilot production and flavour optimisation with global partners.
Why InvisiRelief™?
Developed with leading gum-technology experts for targeted, discreet, and convenient oral pain relief.
Pharmaceutical Approach
Developed with leading gum-technology experts for clinical-grade relief.
Targeted Relief
Direct application to the site of discomfort for localised treatment.
Discreet & Convenient
Looks like regular gum, no water or applicators required.
No Systemic Overload
Local delivery reduces reliance on systemic medication.
Scientific Basis
Medicated chewing gum is a well-established, clinically validated drug-delivery platform with evidence showing it bypasses first-pass metabolism for fast and effective relief.
Established Drug Delivery System
Medicated chewing gum is already used for nicotine replacement (FDA/TGA approved), caffeine delivery in clinical trials, and vitamin/supplement absorption.
Buccal Absorption Advantages
Bypasses first-pass metabolism, improving bioavailability and onset of action while reducing hepatic load and polypharmacy risks.
High Patient Compliance
Discreet, portable, and socially acceptable delivery method that patients actually want to use.
European Pharmacopoeia Recognition
MCG is recognized for both local and systemic administration, with nicotine gum as a proven commercial example.
The Evidence
Studies show MCG formulations improve bioavailability, patient compliance, and onset of action for local and systemic treatments (Jette Jacobsen et al., American Journal of Drug Delivery, 2004; Sadeq et al., IJDDT, 2022). The European Pharmacopoeia recognises MCG for local and systemic administration, and nicotine gum is a proven commercial example (Khatiwara et al., Journal of Applied Pharmaceutical Research, 2021).
Notable example: Nicotine gum uses a chew-and-park protocol to deliver active ingredients via the mouth lining.
Indications
In Development
Being developed for the reduction of discomfort associated with various oral conditions.
Note: InvisiRelief™ is in development and not yet approved by regulatory authorities. It is intended to reduce discomfort, not replace professional medical or dental treatment.
Development Roadmap
Our systematic approach to bringing InvisiRelief™ to market, ensuring safety, efficacy, and regulatory compliance at every stage.
Proof of Concept
CompletedInitial formulation and feasibility studies completed successfully.
Pilot Production & Flavour Finalisation
CurrentOptimizing manufacturing processes and finalizing taste profiles.
Stability & Sensory Validation
NextComprehensive testing for shelf-life and consumer acceptance.
Regulatory & Clinical Validation (AU/US/EU)
PlannedRegulatory submissions and clinical trials across key markets.
Pilot Launch
FutureLimited market release and commercial scale-up preparation.
About Us
SaunLab Pty Ltd (ABN: 48 690 560 206) — Adelaide, South Australia. We are developing next-generation pharmaceutical delivery systems that merge clinical rigour with consumer usability, starting with InvisiRelief™.
Interested in collaboration? Contact us.